• Achieve flagged risk from recently announced tariffs on imported pharmaceutical products, accelerating plans to shift cytisinicline drug product manufacturing to U.S.-based Adare Pharma Solutions.
• FDA assigned an Official Action Indicated classification to a third-party manufacturing facility following a cGMP inspection.
• Achieve expects FDA to issue a Complete Response Letter on or before June 20, 2026 PDUFA goal date.
• Company targets resubmission of cytisinicline New Drug Application in Q4 2026 naming Adare as commercial supplier.
• Commercial launch timeline remains first half of 2027 if cytisinicline clears FDA review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Achieve Life Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604150800PRIMZONECNPR____9690170) on April 15, 2026, and is solely responsible for the information contained therein.